Barclays downgraded ICL Group from Overweight to Underweight and set a new price target of $4.00 from $6.50 previously
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/21/2025 | $4.00 → $6.00 | Underweight → Equal Weight | Barclays |
| 1/12/2024 | $6.50 → $4.00 | Overweight → Underweight | Barclays |
| 11/14/2023 | $7.00 → $6.50 | Equal Weight → Overweight | Barclays |
| 5/18/2023 | Buy → Neutral | BofA Securities | |
| 6/1/2022 | $12.00 | Equal Weight | Barclays |
| 2/14/2022 | $9.00 → $10.00 | Equal-Weight | Morgan Stanley |
| 12/6/2021 | $7.00 → $9.00 | Equal-Weight | Morgan Stanley |
6-K - ICL Group Ltd. (0000941221) (Filer)
6-K - ICL Group Ltd. (0000941221) (Filer)
6-K - ICL Group Ltd. (0000941221) (Filer)
ICL (NYSE:ICL) (TASE: ICL), a leading global specialty minerals company, today announced it plans to release second quarter 2025 results prior to the opening of the TASE market on Wednesday, August 6, 2025. On that day, Elad Aharonson, president and CEO of ICL, and Aviram Lahav, CFO of ICL, will host a conference call to discuss results, provide a general business update and answer questions at 8:30 a.m. New York time (1:30 p.m. London and 3:30 p.m. Tel Aviv). The dial-in number for financial analysts in North America is (800) 549-8228, or (289) 819-1520 for international analysts, and the conference ID is 62033. To participate, please dial in a few minutes before the scheduled time.
REHOVOT, Israel, July 8, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company utilizing cutting-edge artificial intelligence and predictive biology to drive innovation in life-science product development, today announced the successful completion and closing of the previously disclosed transaction involving the divestiture of the majority of the activities and assets of its ag-biologicals subsidiary, Lavie Bio Ltd., to ICL Group Ltd. (NYSE:ICL) (TASE: ICL). As part of the transaction, Evogene has also transferred to ICL its proprietary MicroBoost AI for AG platform, which is used to accelerate microbial product development in the agriculture
TEL AVIV, Israel, May 21, 2025 /PRNewswire/ -- Israel Corporation Ltd. (TASE: ILCO) ("ILCO") announced today its first quarter results for the period ending March 31, 2025. Selected Financial Figures for the First Quarter 2025: $m Q1/25 Q1/24 ILCO share in ICL profit 40 48 ILCO share in Prodalim profit - - Amortization of excess cost in held companies (2) (1) Financing income, G&A and other expenses at ILCO headquarter level (5) (1) Tax income of ILCO Headquarters 2 16 Net profit to company's shareholders 35 62 Liquidity at the ILCO Headquarters Level[1]As of March 31, 2025, total financial liabilities were $723 million, and investments in liquid assets amounted to $781 million of whic
Barclays upgraded ICL Group from Underweight to Equal Weight and set a new price target of $6.00 from $4.00 previously
Barclays downgraded ICL Group from Overweight to Underweight and set a new price target of $4.00 from $6.50 previously
Barclays upgraded ICL Group from Equal Weight to Overweight and set a new price target of $6.50 from $7.00 previously
ICL (NYSE:ICL) (TASE: ICL), a leading global specialty minerals company, today announced its Board of Directors has approved the appointment of Elad Aharonson as ICL's new president and chief executive officer, effective March 13, 2025. He will succeed Raviv Zoller who will work with Aharonson to ensure a smooth and orderly transition. Elad Aharonson has been an integral part of ICL for nearly four years, serving as president of ICL's Growing Solutions business since April of 2021. During his tenure, he led the development of ICL's specialty fertilizer solutions and the expansion of these product offerings into new territories, through both organic efforts and via acquisitions. His signif
Zoller to continue to serve the company until a replacement has been announced ICL (NYSE:ICL) (TASE: ICL), a leading global specialty minerals company, today announced that Raviv Zoller, the company's president and CEO for the past seven years, is expected to leave the company in early 2025, following both the appointment of a replacement and a formal transition. In a letter to the company's employees, Zoller wrote, "I feel great pride, mixed with sorrow, as I announce my expected retirement from the position as president and CEO of ICL. Over the past seven years at this amazing organization, I have come to know our employees who give their heart and soul to the company. Together, we ha
Company's Agmatix AI-driven data platform and RegenIQ framework designated as a Friend of Farmers ICL (NYSE:ICL) (TASE: ICL), a leading global specialty minerals company, today announced that Agmatix, the company's ag tech digital start-up, has been named to Fortune's 10th Annual Change the World list. The list recognizes companies that have had a positive social impact through activities that are part of their core business strategy. Among other factors, nominees are assessed on their measurable impact on people and the planet, profitability related to their impactful work, and the degree of innovation they have demonstrated. Agmatix was recognized for its AI-driven platform, which helps
ICL (NYSE:ICL) (TASE: ICL), a leading global specialty minerals company, today announced it plans to release second quarter 2025 results prior to the opening of the TASE market on Wednesday, August 6, 2025. On that day, Elad Aharonson, president and CEO of ICL, and Aviram Lahav, CFO of ICL, will host a conference call to discuss results, provide a general business update and answer questions at 8:30 a.m. New York time (1:30 p.m. London and 3:30 p.m. Tel Aviv). The dial-in number for financial analysts in North America is (800) 549-8228, or (289) 819-1520 for international analysts, and the conference ID is 62033. To participate, please dial in a few minutes before the scheduled time.
TEL AVIV, Israel, May 21, 2025 /PRNewswire/ -- Israel Corporation Ltd. (TASE: ILCO) ("ILCO") announced today its first quarter results for the period ending March 31, 2025. Selected Financial Figures for the First Quarter 2025: $m Q1/25 Q1/24 ILCO share in ICL profit 40 48 ILCO share in Prodalim profit - - Amortization of excess cost in held companies (2) (1) Financing income, G&A and other expenses at ILCO headquarter level (5) (1) Tax income of ILCO Headquarters 2 16 Net profit to company's shareholders 35 62 Liquidity at the ILCO Headquarters Level[1]As of March 31, 2025, total financial liabilities were $723 million, and investments in liquid assets amounted to $781 million of whic
Sales of $1.8 billion increased year-over-year, with operating income of $185 million, adjusted EBITDA of $359 million and adjusted diluted EPS of $0.09 ICL (NYSE:ICL) (TASE: ICL), a leading global specialty minerals company, today reported its financial results for the first quarter ended March 31, 2025. Consolidated sales were $1.8 billion versus $1.7 billion in the prior year. Operating income was $185 million versus $203 million of operating income in the first quarter of last year, with adjusted operating income of $208 million versus $215 million. For the first quarter, net income attributable to shareholders was $91 million versus $109 million in the prior year, with adjusted net in
SC 13G/A - ICL Group Ltd. (0000941221) (Subject)
SC 13G - ICL Group Ltd. (0000941221) (Subject)
SC 13G/A - ICL Group Ltd. (0000941221) (Subject)